Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Pasithea Therapeutics (KTTA) will participate in two investor conferences in September 2026 to engage with investors and present its business.
Rhea-AI Summary
Pasithea Therapeutics (KTTA) will participate in two investor conferences in September 2026 to engage with investors and present its business.
Management will hold one-on-one meetings at the 12th Annual Cantor Global Healthcare Conference in New York, NY, from September 9-11, 2026. Management will also present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026, with the company’s presentation scheduled for Monday, September 14, 2026, at 2:30 PM ET. Pasithea is a clinical-stage biotech developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for chronic diseases including neurocutaneous manifestations of NF1.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | ESMO data presentation | Neutral | -3.9% | Scheduled presentation of Phase 1 PAS-004 dose-escalation data at ESMO |
| Jul 08 | Investor conference participation | Neutral | -1.6% | One-on-one meetings and discussions scheduled at B. Riley summit |
| Jun 30 | Phase 1 clinical data | Positive | -2.0% | Interim data showed safety, durable stabilization, and chronic-dosing pharmacokinetics |
| Jun 16 | Clinical protocol amendment | Neutral | -8.9% | Protocol added higher doses, longer treatment, and expanded imaging assessments |
| Jun 15 | Conference exhibition | Neutral | -5.3% | Company scheduled exhibition at the 2026 NF Conference |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
All five selected prior news events were followed by negative 24-hour price reactions, including positive clinical updates.
Key Terms
macrocyclic technical
MEK inhibitor medical
neurofibromatosis type 1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) --
MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type 1 (NF1), today announced that management will participate in two investor conferences taking place in September 2026: the 12th Annual Cantor Global Healthcare Conference, hosted by Cantor Fitzgerald, and the H.C. Wainwright 28th Annual Global Investment Conference.
12th Annual Cantor Global Healthcare Conference
Management will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference, taking place September 9-11, 2026, in New York, NY.
H.C. Wainwright 28th Annual Global Investment Conference
Management will also present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14-16, 2026, with the Company's presentation scheduled for Monday, September 14, 2026, at 2:30 PM ET.
About Pasithea Therapeutics Corp.
Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical and non-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Contact
Patrick Gaynes
Investor Relations
pgaynes@pasithea.com
